Estados Unidos · Bolsa y Finanzas · Quartz

Novartis is licensing an mRNA autoimmune therapy from China's Abogen for up to $7.8 billion

Publicado por Quartz · Estados Unidos hace 4 h

The Swiss drugmaker will pay $575 million upfront to license ABO2203, with up to $7.2 billion more tied to milestones

Leer el artículo completo en Quartz Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (qz.com)

También te puede interesar

Energy's inverse grip on stock market hits a record high

Mash-Up of Paramount and Warner Bros. Will Be Called Skydance

Business Insider

Data centers and healthcare were bright spots in the rough September jobs report

Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

It’s not AI anymore, it’s ‘super intelligence’ (according to the White House)

Once a $2.3 Billion Network, Ethereum Layer-2 Blast Is Shutting Down